1. Home
  2. PHVS vs VZLA Comparison

PHVS vs VZLA Comparison

Compare PHVS & VZLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • VZLA
  • Stock Information
  • Founded
  • PHVS 2015
  • VZLA 2017
  • Country
  • PHVS Switzerland
  • VZLA Canada
  • Employees
  • PHVS N/A
  • VZLA N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • VZLA
  • Sector
  • PHVS Health Care
  • VZLA
  • Exchange
  • PHVS Nasdaq
  • VZLA Nasdaq
  • Market Cap
  • PHVS 1.6B
  • VZLA 1.6B
  • IPO Year
  • PHVS 2021
  • VZLA N/A
  • Fundamental
  • Price
  • PHVS $24.95
  • VZLA $4.45
  • Analyst Decision
  • PHVS Buy
  • VZLA Strong Buy
  • Analyst Count
  • PHVS 7
  • VZLA 1
  • Target Price
  • PHVS $37.00
  • VZLA $7.00
  • AVG Volume (30 Days)
  • PHVS 282.9K
  • VZLA 6.9M
  • Earning Date
  • PHVS 11-12-2025
  • VZLA 12-12-2025
  • Dividend Yield
  • PHVS N/A
  • VZLA N/A
  • EPS Growth
  • PHVS N/A
  • VZLA N/A
  • EPS
  • PHVS N/A
  • VZLA N/A
  • Revenue
  • PHVS N/A
  • VZLA N/A
  • Revenue This Year
  • PHVS N/A
  • VZLA N/A
  • Revenue Next Year
  • PHVS N/A
  • VZLA N/A
  • P/E Ratio
  • PHVS N/A
  • VZLA N/A
  • Revenue Growth
  • PHVS N/A
  • VZLA N/A
  • 52 Week Low
  • PHVS $11.51
  • VZLA $1.67
  • 52 Week High
  • PHVS $26.33
  • VZLA $5.07
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 57.14
  • VZLA 54.06
  • Support Level
  • PHVS $23.76
  • VZLA $3.86
  • Resistance Level
  • PHVS $26.20
  • VZLA $4.78
  • Average True Range (ATR)
  • PHVS 1.77
  • VZLA 0.22
  • MACD
  • PHVS 0.19
  • VZLA -0.00
  • Stochastic Oscillator
  • PHVS 75.19
  • VZLA 61.93

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

Share on Social Networks: